|
|
|
|
||
|
||
|
Vol. 38, Nos. 1 - 49, pp. 1-1288 Jan. 4 - Dec. 20, 2010 A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
ZETIA
– Cancer risk unlikely to increase, FDA, 11
– Muscle injury risk increased and other side effects, FDA, 306
– Fact issues created by doctor's testimony, failure to warn claim, jaw osteonecrosis from use (M.D.N.C.), 1100; punitive damages claim, 1150
– Failure to warn claim, jaw osteonecrosis from use, verdict for maker (N.J. Super. Ct.), 1070
– Confidential discovery documents, injunction barring release upheld (2d Cir.), 900
– Diabetes risk, unresolved fact questions on when risk known (E.D.N.Y.), 25; La. accord with maker for off-label marketing, La. law charge that Eli Lilly engaged in deceptive trade practices, 417 – Learned intermediary doctrine, summary judgment for maker (2d Cir.), 761 – Marketing practices and off-label use, Ark. and Miss. accords with maker (Miss. Cir. Ct.), 189 – Third-party payors overpaid, RICO claim, class decertified (2d Cir.), 971 – Weight gain and diabetes, timeliness of suit more than 2 years after drug use end (E.D.N.Y.), 140 Contact the Webmaster at webmaster@bna.com Copyright © The Bureau of National Affairs, Inc. All Rights Reserved. |
